+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating TQF3250 capsules in overweight or obese adults who have had difficulty controlling their weight despite simple lifestyle interventions. This Phase 1b, randomized, double-blind, placebo-controlled study aims to assess the safety, tolerability, pharmacokinetic properties, and early signs of effectiveness of multiple doses of TQF3250. The trial involves 80 participants aged 18 to 65 years with specified BMI ranges and weight-related health issues. Participants are randomly assigned to one of six TQF3250 dose groups or a placebo group. Those in the treatment groups will gradually increase their dose from a low starting amount to the target dose, taking the capsules orally once daily for 12 weeks. The placebo group will also take capsules once daily for the same duration. The study monitors various pharmacokinetic parameters over several timepoints during the treatment period. Throughout the 12-week treatment, participants undergo regular assessments including body weight, body mass index, waist and hip measurements, blood sugar and insulin levels, blood pressure, and lipid profiles. Safety is monitored through adverse event tracking and clinical examinations from baseline up to 14 weeks. Pharmacokinetic blood sampling occurs at multiple intervals to analyze drug absorption and metabolism. Participants are expected to maintain lifestyle management, comply with medication schedules, and complete diaries and questionnaires during the study period.

Age: 18Years - 65YearsAll GendersPhase 1
10 locations
R

Actively Recruiting

Researchers are studying brenipatide LY3537031 to evaluate its safety, side effects, and effectiveness in adults with Irritable Bowel Syndrome-Constipation IBS-C. The study compares brenipatide given by injection under the skin to a placebo in a phase 2 clinical trial. Participants must meet specific IBS-C criteria and have significant abdominal pain to join. Participants receive the study drug or placebo through subcutaneous injection. The trial lasts about 36 weeks, with treatment and monitoring occurring during this period. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants will keep a daily diary to track symptoms like abdominal pain and bowel movements. Researchers will measure the percentage of weeks participants respond to treatment based on clinical criteria between weeks 9 and 16. Safety and side effects will also be closely monitored throughout the trial.

Age: 18Years - 75YearsAll GendersPhase 2
70 locations
E

Actively Recruiting

Researchers are evaluating the safety, side effects, and effectiveness of brenipatide LY3537031 in adults with Irritable Bowel Syndrome-Diarrhea IBS-D. This study compares brenipatide given under the skin to a placebo and aims to understand how well the drug is tolerated and how it impacts symptoms in participants aged 18 to 75. The trial is a randomized, double-blind, placebo-controlled Phase 2 study sponsored by Eli Lilly and Company. Participants receive either brenipatide or placebo, both administered subcutaneously. The study follows a parallel design where different groups receive either the experimental drug or the placebo. Treatment and evaluation last approximately 36 weeks, with key outcome measurements focused on symptom responses between weeks 9 to 16 and up to week 24. During the study, participants will record symptoms daily in an electronic diary, including abdominal pain and stool consistency. Researchers will monitor safety, side effects, and symptom changes through these reports and scheduled assessments. The main outcome is the percentage of days participants show significant symptom improvement during the critical weeks of treatment. The study includes a full follow-up period to assess lasting effects and safety throughout the 36 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
89 locations
E

Actively Recruiting

Researchers are evaluating the effects of thumbtack needle therapy on sleep in women with chronic insomnia during perimenopause and menopause. This multicenter, randomized, controlled, and blinded trial involves 198 women aged 40 to 65 years. The study aims to compare the effects of thumbtack needle treatment with placebo thumbtack needle treatment over a 4-week period. Participants are randomly assigned to one of two groups the treatment group receives thumbtack needle therapy at 11 specific acupoints, and the control group receives placebo thumbtack needle therapy at the same acupoints with comforting acupressure. Treatments are given twice a week, with needles retained for 3 days before removal and skin disinfection. Patients rest one day between treatments, completing a total 4-week course. During the study, participants will be assessed using multiple sleep-related scales and indexes such as the Insomnia Severity Index, Pittsburgh Sleep Quality Index, and Epworth Sleepiness Scale, among others. Researchers will monitor sleep efficiency, wake times, hormone levels, and insomnia remission rates. Safety and treatment response will be evaluated throughout the 4 weeks, with the primary outcome measured by the Insomnia Severity Index at 4 weeks.

Age: 40Years - 65YearsFEMALEPhase Not Applicable
8 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a new 24-valent pneumococcal conjugate vaccine called PCV24 in children aged 2 months to 5 years. This phase 2 clinical trial is randomized, double-blind, and compares PCV24 to an existing vaccine, Prevenar13, to better understand its effects in young children. The study is sponsored by Sinovac Life Sciences Co., Ltd and aims to gather important data on this vaccines performance in the pediatric population. Participants will be randomly assigned to receive either the Sinovac PCV24 vaccine or the Prevenar vaccine. Both vaccines are given as 0.5 mL injections into the muscle, following age-appropriate immunization schedules. The trial includes different age groups within the 2 months to 5 years range, ensuring the vaccine is assessed across a broad pediatric population. During the study, children will be monitored for immune response by measuring pneumococcal serotype-specific antibodies 30 days after vaccination. Safety is also closely observed, tracking any adverse reactions within 30 days and serious events up to six months after the last dose. Guardians will be required to follow study procedures and maintain contact throughout the trial, which will continue until December 2027.

Age: 42Days - 5YearsAll GendersPhase 2
3 locations
P

Actively Recruiting

Researchers are evaluating a new treatment regimen called MAAZA, which combines mitoxantrone hydrochloride liposomes with cytarabine and azacitidine, for adults newly diagnosed with primary Acute Myeloid Leukemia AML. This study compares the MAAZA regimen with the traditional DAAZA chemotherapy regimen to assess their effectiveness and safety in improving treatment outcomes for AML patients. The trial is a prospective, multicenter, randomized controlled study aiming to provide high-quality clinical evidence to improve AML treatment and prognosis. Participants are randomly assigned to one of two treatment groups. The MAAZA group receives mitoxantrone hydrochloride liposome 24 mgm2 intravenously on day 1 every 4 weeks, cytarabine 100 mgm2 intravenously every 12 hours for 7 days, and azacitidine 100 mg subcutaneously once daily for 7 days. The comparison group receives daunorubicin 60 mgm2 intravenously once daily for 3 days, cytarabine 100 mgm2 intravenously every 12 hours for 7 days, and azacitidine 100 mg subcutaneously once daily for 7 days. Each treatment cycle lasts 28 days. During the study, participants undergo evaluations including complete remission rates 2 to 3 weeks after the first treatment cycle. Researchers also monitor adverse events, remission rates, survival times, and mortality up to 100 months after randomization. Regular assessments include blood tests and physical health evaluations. The study lasts for multiple cycles and includes long-term follow-up to assess the overall impact of the treatments on patient survival and disease progression.

Age: 18Years - 75YearsAll GendersPhase 3
11 locations
E

Actively Recruiting

Researchers are evaluating a treatment for people with spontaneous supratentorial intracerebral hemorrhage ICH, a serious type of stroke caused by bleeding in the brain. The study is a phase III randomized controlled trial that will involve 768 participants to compare a new minimally invasive surgery combined with a clot-dissolving drug against standard medical care. This trial aims to assess the safety and effectiveness of using tenecteplase to liquefy and drain brain hematomas, potentially improving recovery outcomes. Participants will be randomly assigned to one of two groups. One group will receive minimally invasive stereotactic catheter placement followed by the local injection of tenecteplase to liquefy and drain the hematoma, with doses of 0.5 mg given up to four times over several days. The other group will receive standard medical treatment in line with current guidelines. The surgery uses imaging to target the hematoma, and after catheter placement, tenecteplase is carefully administered through the catheter with close monitoring. Throughout the study, participants will undergo regular assessments including neurological exams, brain imaging, and functional outcome evaluations up to 180 days after treatment. The main measurement is the modified Rankin Score assessing disability and recovery. Other outcomes include neurological improvement, hematoma size, mortality, and quality of life. Follow-up visits may be conducted face-to-face or remotely, and researchers will carefully monitor safety and treatment effects during this period.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
51 locations
U

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an artificial intelligence-based multimodal cognitive screening system to identify mild cognitive impairment MCI related to diabetes early in patients with type 2 diabetes mellitus T2DM. This observational study follows participants for 3 to 5 years to assess the systems accuracy and feasibility. The study also explores how diabetic metabolic indicators, such as glycemic variability and HbA1c levels, relate to changes in cognitive function, aiming to improve early detection and intervention for cognitive decline in T2DM patients. Participants are observed without additional interventions over the 3 to 5 years of follow-up. The study includes groups of participants with normal cognition and those with mild cognitive impairment. Cognitive status data are collected at the beginning and end of the study period, with no study drug or treatment administered. During the study, participants undergo cognitive assessments and monitoring of diabetic metabolic factors. Researchers measure the accuracy of the AI screening system in early detection and track the rate of cognitive decline over the follow-up period. The study also evaluates the predictive value of combining multiple types of data. Participants remain under observation with regular assessments, helping to understand the relationship between diabetes and cognitive changes over time.

Age: 40Years - 75YearsAll Genders
21 locations